Balanced news tone
News Sentiment
SNW sentiment intelligence
Sanofi news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
88/100 classification confidence.
directly relevant articles
high-authority source matches
+0.3% over one week, -0.8% over four weeks, trend inactive, and near fair-value range.
Thomapyrin Tension Headache by Sanofi S.A. - targeted relief for muscle-related pain
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Thomapyrin Tension Headache by Sanofi S.A. - targeted relief for muscle-related pain
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 06:59
- Source
- ad-hoc-news.de
Thomapyrin INTENSIV by Sanofi - dual-action pain relief in focus
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 09:40
- Source
- ad-hoc-news.de
Sanofi SA (HAM:SNW2) Stock Price, Trades & News
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jul 2026 08:17
- Source
- GuruFocus
Thomapyrin Classic by Sanofi S.A. - pain relief staple under close investor watch
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jul 2026 12:56
- Source
- ad-hoc-news.de
Brussels launches antitrust probe into French drugmaker Sanofi
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 26 Jun 2026 07:00
- Source
- Financial Times
EU launches antitrust probe into Sanofi over flu vaccine claims
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 26 Jun 2026 07:00
- Source
- scanx.trade
Sanofi Stock - Thursday technicals after recent slide
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- ad-hoc-news.de
Sanofi S.A. stock (FR0000120578): FDA priority review underpins pipeline focus ahead of key 2026 dec
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 May 2026 07:00
- Source
- ad-hoc-news.de
Sanofi shares fall after CEO change
- Tone
- Negative 22/100
- Event
- Market update
- Published
- 12 Feb 2026 13:40
- Source
- MSN
Sanofi, looking for more ‘rigor,’ swaps CEO Hudson for ex-Merck KGaA chief Garijo
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Feb 2026 08:00
- Source
- BioPharma Dive
Sanofi ousts CEO Hudson after stalled turnaround at vaccine giant
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Feb 2026 08:00
- Source
- CNBC
Sanofi ousts Paul Hudson after 'bumpy ride,' enlists Merck KGaA CEO to lead the French pharma
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Feb 2026 08:00
- Source
- Fierce Pharma
Sanofi's new CEO needs to fix drug pipeline and navigate Trump
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Feb 2026 08:00
- Source
- Reuters
Sanofi replaces chief Paul Hudson with Merck executive after R&D woes
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Feb 2026 08:00
- Source
- Financial Times
French authorities raid Sanofi headquarters in tax fraud probe
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 26 Nov 2025 08:00
- Source
- Fierce Pharma
Sanofi invests €1.3bn in insulin production plant in Germany
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Aug 2024 07:00
- Source
- BioProcess International